Guangdong Raynovent Biotechnology Co., Ltd announced that it has received CNY 370 million in a round of funding led by investors Shenzhen Qianhai Xinyi Yide Fund Management Co., Ltd., Efung Capital on January 3, 2023. The transaction also included participation from Guangzhou Guoju Venture Capital Co., Ltd., Wanlian Guangsheng Investment Co., Ltd. and returning investors Guangdong Zhongsheng Pharmaceutical Co., Ltd., Lake Bleu Capital (Hong Kong) Limited.